The efficacy and safety of Kampo (Japanese herbal) medicines, maoto and maotokasekko, in treatment of influenza virus infections

The efficacy and safety of Kampo (Japanese herbal) medicines, maoto and maotokasekko, in treatment of influenza virus infections - The efficacy and safety of Kampo medicines in treatment of influenza virus infections

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000000848

Enrollment

Registered

2007-11-01

Start date

2007-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

influenza virus infections

Interventions

administration of maoto consumption of 2 packs of maoto directly after the consultation, subsequent application of 2 packs after 4 and 8 hours and 1 pack after 16, 24, and 32 hours, respectively admi

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients with influenza virus infection who meet all the requirements below 1. oral temperature equal or higher than 37.8 degree C 2. two or more symptoms shown below headache muscle pain cough sore throat 3. within the first 36 hours after the onset of symptoms 4. identification of influenza virus by PCR methods

Exclusion criteria

Exclusion criteria: 1. patients who is taking any Kampo medicines 2. patients who took any Kampo medicines in the past 4 weeks 3. patients who need to start taking other medicines simultaneously 4. patients with active cardiovascular diseases 5. patients with active hyperthyroidism 6. patients in danger of urinary retention 7. patients with severe delicate constitution 8. patients with hypokalemia 9. patients with significant liver or renal dysfunction 10. patients with allergic reaction to the test drugs 11. patients with some disease which may deteriorate their performance status such as cancer or heart failure 12. patients considered inappropriate for this trial by the physicians-in-charge

Design outcomes

Primary

Measure	Time frame
time to the alleviation of all major symptoms definition of "alleviation of all major symptoms" 1. without sensation of heat 2. oral temperature is 37.8 degree C or lower 3. disappearance or mild state of all the symptoms below 1. sore throat 2. cough 3. muscle pain 4. headache 4. above state is kept more than 24 hours	—

Secondary

Measure	Time frame
time to the absence of fever time to the alleviation of individual symptoms time to the resumption of normal activities adverse drug events	—

Countries

Japan

Contacts

Public ContactHiroshi Odaguchi

Oriental Medicine Research Center, Kitasato University Clinical Trial Division

odaguchi@insti.kitasato-u.ac.jp03-3444-6161

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026